COPD Pharmacology: GOLD 2026 Inhalers, Exacerbations and Emerging Treatments

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information.

Overview

Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow obstruction. Confirm diagnosis with post-bronchodilator spirometry showing FEV1/FVC below 0.70 in the appropriate clinical context. Pharmacotherapy reduces symptoms and exacerbations but must accompany smoking cessation, vaccination, physical activity and pulmonary rehabilitation [1,2].

Drug classes and receptors

  • Short-acting rescue bronchodilators: salbutamol/albuterol (SABA, β2 agonist) and ipratropium (SAMA, muscarinic antagonist).
  • Maintenance LABAs: formoterol, salmeterol, indacaterol, olodaterol; β2 receptor activation increases cAMP and relaxes smooth muscle.
  • LAMAs: tiotropium, umeclidinium, glycopyrronium; inhibit M3 receptor-mediated bronchoconstriction.
  • Inhaled corticosteroids (ICS): budesonide, fluticasone; modulate airway inflammatory transcription but should not be routine standalone COPD therapy.
  • Selected add-on treatments: roflumilast (PDE4 inhibitor), ensifentrine (inhaled PDE3/4 inhibitor, depending on national approval), azithromycin for particular exacerbation-prone patients, and phenotype-selected biologics [1,2].

GOLD 2026 treatment principles

Long-acting bronchodilators are the foundation of maintenance care; LABA/LAMA is favored for many symptomatic or exacerbation-prone patients. An ICS-containing triple regimen (LABA/LAMA/ICS) is considered when exacerbation burden and blood eosinophils favor benefit, especially around or above 300 cells/µL. Low eosinophil counts predict less benefit and pneumonia risks matter; eosinophils are a continuous marker rather than an absolute cutoff. LABA/ICS without LAMA is generally not encouraged when starting COPD therapy in the absence of concomitant asthma. A single moderate exacerbation warrants reassessment of risk and treatment [2].

Additional therapies and exacerbations

Roflumilast may be considered in severe airflow limitation with chronic bronchitis and repeated exacerbations, particularly with FEV1 below 50% predicted. Ensifentrine may improve symptoms and airflow in eligible patients where approved; it is not a replacement for indicated background therapy. GOLD 2026 includes dupilumab and mepolizumab as add-on biologic options for selected patients with persistent exacerbations and eosinophilic features despite optimized inhaled treatment; indications and payer criteria differ. Acute exacerbations require short-acting bronchodilators, systemic corticosteroids for appropriate cases, antibiotics when clinically indicated, and oxygen/ventilatory support as needed [2].

Pharmacokinetics and adverse effects

Inhaled drugs largely act locally but vary in systemic absorption and duration. LABAs can cause tremor, tachycardia and hypokalemia; LAMAs cause dry mouth and may aggravate urinary retention or glaucoma if aerosol contacts the eyes. ICS can cause dysphonia, oral thrush and increased pneumonia risk in selected COPD patients. Roflumilast can cause diarrhea, weight loss, insomnia and mood effects; monitor weight and psychiatric history. Azithromycin carries QT, hearing and resistance concerns [1,2].

Monitoring and stewardship

Verify inhaler technique, adherence, exacerbation history, symptoms, spirometry and comorbidities before escalation. Coexisting asthma requires an ICS-containing regimen. Long-term oxygen is reserved for established severe hypoxemia, not breathlessness alone. Titrate treatment according to response, safety and current local GOLD pathways [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report. Available from: https://goldcopd.org/2026-gold-report-and-pocket-guide/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *